Orphazyme's creditors to vote on sales agreement at end of May

Sunday’s sales agreement between US-based Kempharm and Orphazyme will be decided on May 30, when the company’s creditors meet to vote on the proposal.

Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix

Embattled biotech firm Orphazyme finally has a restructuring proposal after Sunday’s announcement that Kempharm, which is based in the US, has agreed to buy the firm’s assets and activities.

Yesterday, Orphazyme sent out a press release convening creditors to vote on the proposed restructuring – and in extension, the sale to Kempharm – on May 30 at the Maritime and Commercial High Court in Copenhagen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs